CLEAR

Principal Investigator: Dr Antony James- Consultant Psychiatrist

Objective: The trial will assess whether Clozapine is more effective than treatment as usual in people 12-25, at the level of clinical symptoms, patient related outcomes, quality of life and cost effectiveness.

 

DPIM

Principal Investigator: Dr Digby Quested- Consultant Psychiatrist

Objective: To find genetic or other cause of mental illness by studying DNA in the blood or saliva .

 

Early Intervention Mission

Principal Investigator: Professor Belinda Lennox – Professor of Psychiatry

Objective: To understand more about psychosis by comparing information collected from individuals with psychosis to the general population. Information will be collected from medical records, a blood sample and other questionnaires.

 

ENGIMA-TRS

Principal Investigator: Dr Robert McCutcheon – Consultant Psychiatrist

Objective: Evaluate the efficacy of Evenamide as an add on antipsychotic treatment in patients with treatment resistant schizophrenia. Evenamide is a sodium channel blocker and works to reduce positive psychotic symptoms.

 

GlobalMinds

Principal Investigator: Dr Philip McGuire – Consultant Psychiatrist

Objective: To develop an internationally diverse bioresource linking genetic and healthcare information in individuals with schizophrenia, psychosis, depression or bipolar.

 

Investigating Neural Basis for Psychosis

Local Collaborator: Professor Belinda Lennox – Professor of Psychiatry 

Objective: Investigating how memory formation and consolidation processes are altered in individuals with First Episode Psychosis using functional neuroimaging.

 

MAPS- MENSTRUAL CYCLE AND PSYCHOTIC SYMPTOMS

Principal Investigator: Dr Thomas Reilly

Objective: This study aims to measure how mental health symptoms changes across the menstrual cycle.

 

moreRESPECT

Principal Investigator: Abiola Jokomba – Ward Manager

Objective: To understand if a tailored sexual health intervention able to reduce unprotected sexual acts and increase knowledge about sexually transmitted diseases and healthy relationships.

 

Neurocrine

Principal Investigator: Professor Rachel Upthegrove – Professor of Psychiatry

Objective: To evaluate the efficacy of NBI-1117570 compared with placebo on improving behavioural and psychological symptoms of
schizophrenia in adults who warrant inpatient hospitalization. To evaluate the safety and tolerability of NBI-1117570 in
participants with schizophrenia.

 

PEACE

Principal Investigator: Dr Daniel Maughan – Consultant Psychiatrist

Objective: To explore the cause of cognitive symptoms of schizophrenia by measuring brain activity using brain scans.

 

PPIP2

Principal Investigator: Professor Belinda Lennox – Professor of Psychiatry

Objective: To test enough patients with psychosis to be able to define the prevalence of schizophrenia that is caused by an antibody mediated disorder.

 

Sleeping Better

Principal Investigator: Dr Daniel Freeman – Consultant Clinical Psychologist

Objective: We are offering a 12 week cognitive-behavioural sleep intervention for individuals with a diagnosis of psychosis or at ultra-high risk for psychosis. We aim to improve sleep, mood, psychiatric symptom and overall functioning.

 

SMILE

Principal Investigator: Professor Rachel Upthegrove – Professor of Psychiatry

Objective: To investigate the genetic and environmental interactions of people with psychosis spectrum disorders. All participants will be re-contactable and join the NIHR BioResource, offering participants relevant research opportunities in the future.

 

Tri-Prep

Principal Investigator: Dr Andrew Molodynski – Consultant Psychiatrist

Objective: investigate the views, understandings and perspectives of people with severe mental illness and mental health professionals on smoking/vaping, reduction and cessation. This study will inform the design of future research on helping people with severe mental illness to reduce smoking, finding out how we can make our research acceptable and suitable for participants.